Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

GNA Biosolutions to Showcase PCA Technology for Ultrafast PCR and Pharos V8 instrument at Analytica 2018

GNA Biosolutions
Posted on: 10 Apr 18
GNA Biosolutions to Showcase PCA Technology for Ultrafast PCR and Pharos V8 instrument at Analytica 2018

Munich, Germany April 9, 2018: GNA Biosolutions GmbH will be showcasing the Pharos V8, the world’s first Laser PCR instrument based on the company’s proprietary Pulse Controlled Amplification (PCA) technology at the Analytica trade fair (Booth A3/522) in Munich, Germany from April 10-13. Launched in November 2017, the Pharos V8 delivers ultrafast PCR results in 10 minutes or less.

Conventional PCR platforms rely on bulky thermocyclers that limit the speed of the reaction. The Pharos V8 is the world’s first Laser PCR instrument powered by PCA, a novel patented technology developed by GNA Biosolutions.

Key features of PCA:

  • Unique patented technology for ultrafast nucleic acid amplification
  • Utilizes microcyclers in solution as miniature thermal hubs for the PCR reaction
  • Rapid energy pulses control speed, resulting in ultrafast PCR reaction times

Key features of the Pharos V8:

  • First commercially available Laser PCR instrument, based on PCA technology
  • Ultrafast PCR results in 10 minutes or less, on an easy to use interface
  • Universal DNA kit for lab-developed tests (bacterial, human genomic & viral DNA) in both single and multiplex formats

Lars Ullerich, Managing Director GNA Biosolutions states, "PCA is a completely unique and exciting approach to PCR that takes something fundamental and pushes it further. The Pharos V8 instrument delivers results with high sensitivity and unparalleled speed and makes PCR even more useful; it creates new possibilities for a range of different applications across multiple industries."

In addition to the Pharos V8, GNA Biosolutions is implementing Laser PCR in an integrated sample-preparation system, as part of a consortium focused on MRSA detection (KAREL). The company also recently completed successful Laser PCR field tests for Ebola RNA virus detection in Sierra Leone as part of a publicly funded project (FILODIAG).

About GNA Biosolutions: GNA Biosolutions is a molecular technology company specializing in sample-to-result applications across medical diagnostics, biosecurity, food and water safety, agriculture and life sciences. GNA Biosolutions develops instruments, OEM modules and ultrafast molecular tests based on proprietary technologies protected by a comprehensive patent portfolio. GNA Biosolutions aims to bring the power of molecular technology to any environment by building ultrafast, accessible and useful molecular testing platforms, for the lab and the real world. For more information, visit: www.gna-bio.com

For more information:
www.gna-bio.com

Editor's Details

Leigh Dilley
Biostrata
biostratamarketing.com
1223253787
ldilley@biostratamarketing.com

Last updated on: 10/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.